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Background: A survey was performed in 2008 to evaluate the profiles of patients with chronic hepatitis B cared for
by Italian Infectious Diseases Centers (IDCs).
This analysis describes: i) factors associated with access to the anti-HBV treatment in a cohort of HIV/HBV co-
infected patients cared for in tertiary centers of a developed country with comprehensive coverage under the
National Health System (NHS); ii) consistency of current anti-HBV regimens with specific European guidelines in
force at the time of the study and factors associated with the receipt of sub-optimal regimens.
Methods: The study focuses on 374 (87.6%) treated patients at some point in their life out of the 427 tested HIV/HBV
positive. It is multicentre, cross-sectional in the design. To account for missing values, a Multiple Imputation method is
used.
Results: Three hundred and thirty-four (89.3%) patients were currently treated. The most common current regimen was
combination therapy of tenofovir (TDF) plus LAM/FTC (lamivudine/emtricitabine) (n = 235, 70.4%), as part of antiretroviral
treatment.
In the multivariate analysis, an increased chance of getting treated was independently associated with increasing years
since HBV diagnosis (2–10 years, p <0.001; >10 years, p <0.001).
Patients consistently treated with European AIDS Clinical Society (EACS) 2008 guidelines were 255 (76.6%), of whom 202
(79.2%) with an indication to an anti-HIV treatment, 30 (11.8%)without an indication, and 21 (8.2%) with cirrhosis. Among
the 78 not-consistent patients, LAM mono-therapy (n = 60, 76.9%) was the most common regimen, 34 (56.7%) of them
showing HBV DNA load below 1x103 IU/mL.
Previous anti-HBV treatment (p = 0.01) and a triple HDV co-infection (p = 0.03) reduced the chance of not-consistent
regimens. Conversely, HCV co-infection was independently associated with an increased odds ratio of being inconsistently
treated (p = 0.004).
Conclusion: Our study shows that Italian IDCs treat for HBV infection the vast majority of HIV/HBV co-infected patients
with no disparities limiting access to antiviral therapy. In approximately two-thirds of the patients on treatment, anti-HBV
regimens are consistent with 2008 EACS guidelines. Finally, our study identifies scenarios in which clinical practice deviates
from recommendations, as in case of sub-optimal regimens with effective anti-HBV response.
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Human immunodeficiency virus (HIV) and hepatitis B
virus (HBV) may both result in chronic diseases, cancer,
and death, representing an heavy burden for the Health
Care Systems of different countries. At present, about
33 million individuals are estimated living with HIV
infection and 400 million with HBV infection worldwide
[1,2].
Shared ways of transmission for both viruses favour
theoccurrence of HIV/HBV co-infection, whose frequency
reflects the endemicity level of each single infection in
different geographic areas [3]. In European countries, ap-
proximately 10% of the HIV-infected persons are concur-
rently co-infected with HBV [4]. Furthermore, as deaths
from AIDS-related causes have declined following the
introduction of combined antiretroviral therapy [cART),
HBV infection has emerged as a cause of death in co-
infected populations [5].
Such considerations along with new anti-HBV drugs
becoming available prompted in 2008 European AIDS
Clinical Society (EACS) to update guidelines for the clin-
ical management and treatment of chronic hepatitis B
(CHB) and hepatitis C virus (HCV) co-infection in HIV-
infected adults [6]. However, how published guidelines
for clinical management of HBV co-infection reflect
treatments received by patients in real-life until now is
poorly documented. In particular, it is unclear how often
clinician choose guideline-consistent treatments, and
what factors may address them to sub-optimal regimens.
Noteworthy, disparities in the access to treatment not
related to the severity of the disease, but potentially able
to counteract any beneficial effects of therapy on CHB
hepatitis B have been reported even in industrialized
countries [7].
In 2008 the Italian Society of Infectious and Tropical Dis-
eases (SIMIT) conducted a multi-center nationwide survey
to evaluate the profiles of patients with CHB cared for by
Infectious Diseases Centers (IDCs). In agreement with the
Italian National Health Service (NHS), which provides uni-
versal access and comprehensive coverage, IDCs are in-
cluded among the tertiary referral centers allowed to care
for patients with CHB. Moreover, Italian NHS stated that
only IDCs are allowed to dispense antiretroviral therapy [8].
Therefore, this survey provides an unique opportunity
to explore factors, if any, associated with the access to
antiviral treatment in a cohort of HIV/HBV co-infected
patients cared for in tertiary centers of a developed
country where barriers to treatment are theoretically not
expected due to comprehensive coverage under NHS.
We also analyzed changes over time of the anti-HBV
regimens, and the consistency of current regimens with
specific European guidelines in force at the time of the
study. Finally, we identified factors associated with the
receipt of sub-optimal regimens.Methods
Study population and definitions
All of the 110 Italian IDCs were invited by the SIMIT to
take part in this cross-sectional survey, and 74 agreed to
participate. HIV/HBV co-infected patients were recruited
in 41 out of the 74 participating IDCs. Details of the study
design and of data collection have been presented else-
where [9]. Briefly, in each center, all subjects older than
18 years of age with persistent (more than 6 months)
HBsAg positivity, and who received care from March 1,
2008 to September 30, 2008 were enrolled in the study. In
compliance with the Helsinki Declaration, each enrolled
patient signed an informed consent form to abstract
and anonymously collect data on their own demographic
characteristics, clinical and laboratory values, and treat-
ment history by the referring investigator of each partici-
pating centre. A precoded form was used. In accordance
with Italian rules, this study was firstly approved by the
Ethical Committee of the leading center (Santa Maria
Annunziata Hospital, ASL Firenze, Firenze), and then
Ethical Committees of all participating centers approved
the study protocol.
Chronic hepatitis was diagnosed by liver histology or,
for patients without liver biopsy, on the basis of persis-
tent or recurrent abnormal alanine aminotransferase
along with HBV DNA greater than 2×103 IU/ml, in the
absence of clinical, biochemical, and ultrasound markers
of cirrhosis. Cirrhosis was diagnosed by either liver bi-
opsy or the presence of unequivocal clinical, biochem-
ical, and ultrasound signs [10]. The diagnosis of HCC
was based on histology, imaging techniques, or a com-
bination of imaging techniques and biochemical parame-
ters [11].
Hepatitis B serum markers (HBsAg, HBeAg and anti-
HBe) and anti-HDV antibodies were determined by com-
mercial immunoenzyme assays. Antibodies to HCV were
detected by third-generation commercial immunoenzy-
matic assays. Serum HBV DNA or HIV RNA levels were
assessed by polymerase chain reaction amplification.
For the purpose of the present analysis, we included
patients tested HIV positive. In order to exclude patients
with treatment prescribed but ever started, we consid-
ered only anti-HBV treatments taken by patients for at
least 1 month. Treatments taken at the time of the sur-
vey were considered as current. Patients who restarted
the same nucleos(t)ide analogues (NUC) based regimen
after a discontinuation of less than one year were con-
sidered as treated once.
EACS treatment guidelines for treatment of HBV
co-infected adults
In patients with no indication for anti-HIV therapy (nadir
CD4 count >350 cells/mL) EACS guidelines recommended
(i) pegylated interferon-α (PEG-IFN); (ii) telbivudine (LdT),
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at week 24; (iii) de novo ADV plus LdT; (iiii) early cART
initiation including tenofovir (TDF) plus lamivudine/
emtricitabine (LAM/FTC). In patients with an indication
for anti-HIV therapy (nadir CD4 count ≤350 cells/mL) or
already on cART, TDF plus LAM/FTC was recommended.
In case of resistance of HBV to LAM, TDF should be
added or substituted to one nucleoside reverse transcrip-
tase inhibitor. For cirrhotic patients TDF plus LAM/FTC
was the treatment of choice.
For the present analysis, all the above mentioned regi-
mens were considered as guideline consistent (GC); regi-
mens not mentioned in EACS guidelines were classified
as unlisted (GU). According to EACS guidelines patients
with triple HCV co-infection using interferon-based reg-
imens were considered consistently treated.
Statistical analysis
Studied population was divided into two groups according
to the treatment status at the moment of the survey: never
treated patients, and those treated at some time in their
life. Groups were compared with respect to a priori-
selected demographic and clinical characteristics by using
the Pearson χ2 test and Wilcoxon test respectively for cat-
egorical and continuous variables.
The association of treatment status with selected co-
variates was studied by using a multivariable logistic
model. Results were shown in terms of adjusted Odds
Ratios (aOR) with relative 95% Confidence Interval (CI).
Currently treated HIV/HBV co-infected patients were
classified according the prescribed antiviral regimen and
consistency of regimen with EACS treatment guidelines.
Factors associated with consistency of current treat-
ment with EACS recommendations were studied by
using a multivariable logistic model.
To account for the loss in precision and possible bias
in the estimates due to missing values in the covariates
we were interested in, we used the Multiple Imputation
method. Multiple Imputation is based on Missing at Ran-
dom assumption, stating that the probability of data being
missing depends only on the observed data. Consequently,
the distribution of the observed data is used to estimate a
set of values for the missing data. Multiple data sets are
derived and identically analyzed to compute a set of esti-
mates for the parameters of interests. Finally, the estimates
are combined according to the Rubin’s rule [12] to obtain
the overall estimates, variances and CI’s. Forty imputed
datasets were obtained by using the Multiple Imputation
by Chained Equations [13,14] approach as implemented
in user contributed ice command [15] in Stata [16], then
mim command [17] was used to analyze the datasets and
combine the estimates.
Within-center correlation was accounted for by com-
puting a robust sandwich estimate of variance-covariancematrix when estimates of imputed data sets were
combined.
All tests were two sided and p-values < 0.05 were con-
sidered significant.
Results
The 427 (11.4%) patients classified as HIV/HBV co-
infected are considered in the present analysis. Median age
at diagnosis was 35 years (interquartile range, 30–42),
75.9% were males, and the majority (83.2%) was born in
Italy, 1.6% in East Asia, 9.4% in Sub Saharan Africa and
2.3% in East Europe. A total of 149 (34.9%) patients were
HBeAg positive, 78 (18.3%) were HDV co-infected, and
138 (32.3%) HCV co-infected. Seventy-eight (18.3%) pa-
tients were alcohol abstinent. Cirrhosis or HCC was
present in 37 (8.7%) of the cases. Information on HCV co-
infection was missed in 1 (0.2%) patient, HDV co-infection
in 27 (6.3%), and alcohol consumption in 139 (32.6%).
Three hundred and seventy-four (87.6%) patients have
been treated for CHB at some point in their life (Table 1).
Demographic, clinical and virological characteristics were
entered in a logistic regression model to identify factors as-
sociated with no treatment. The only independent associ-
ation we observed was with increasing years since HBV
diagnosis, which reduced the chance of not being treated
(2–10 years: aOR 0.17, 95% CI 0.08-0.37, p <0.001; >10
years: aOR 0.08, 95% CI 0.03-0.26, p <0.001;) (Table 2).
Three hundred and thirty-four (89.3%) out of the 374
treated patients were on current anti-HBV treatment, of
whom 214 (64.1%) had never been treated before. The
most common current anti-HBV regimen was combi-
nation therapy of TDF plus LAM/FTC (n = 235, 70.4%),
followed by LAM alone (n = 60, 18%), and TDF alone (n =
17, 5.1%). Only 6 (1.8%) patients were on interferon-based
treatment, of whom 4 in combination with TDF (Table 3).
One hundred and sixty patients (42.8%) had had a his-
tory of past treatment; 99 (61.9%) had been previously
treated with LAM. At the time of this survey, 70 (68.0%)
of these latter patients had been switched to TDF plus
LAM/FTC, 10 (9.7%) were using other NUC regimens,
only 1 had changed to an interferon-based regimen, and
22 (21.4%) were not being treated. Patients with a previ-
ous interferon-based regimen were 36. Twenty (55.6%)
were currently on TDF plus LAM/FTC, 7 (19.4%) were
on different NUC regimens, 1 patient was retreated, and
8 (22.2%) were not treated. Other NUC-based regimens
were previously used by 21 (13.1%) patients, of whom 15
(71.4%) were currently using TDF plus LAM/FTC.
Three patients had been switched to TDF plus LAM/
FTC, 7 to different NUCs, 1 changed to interferon, and
10 (47.6%) were not being treated.
Two hundred and fifty-five (76.6%) patients were cur-
rently treated according to the EACS guidelines for
chronic HBV co-infection in force at the time of the
Table 1 Characteristics of the 427 patients with HIV/HBV co-infection according to anti-HBV treatment status
Characteristics Never treated patients
(n = 53)
Treated patients
(n = 374)
All patients
(n = 427) P
N. enrolled per center, %
≥20 patients 60.4 52.9 53.9 0.31
Female gender, % 22.6 24.3 24.1 0.79
Immigrant status, %
foreign birth 18.9 16.8 17.1 0.71
Median age at diagnosis§, years
(IQR) 35 (31–43) 35 (29–42) 35 (30–42) 0.81
Years since HBV diagnosis°, % <0.001
<2 32.1 7 10.1
2-10 52.8 59.9 59
>10 15.1 32.4 30.2
Alcohol consumption*, % 0.22
never 15.1 18.7 18.3
ever 60.4 47.6 49.2
not available 24.5 33.7 32.6
Disease stage, %
cirrhosis/HCC 3.8 9.4 8.7 0.18
HBeAg, % 0.17
positivity 28.3 35.8 34.9
not available 1.9 0.3 0.5
HCV co-infection, % 0.4
yes 24.5 33.4 32.3
not available – 0.3 0.2
HDV co-infection, % 0.07
yes 7.5 19.8 18.3
not available 9.4 5.9 6.3
§computed on 424 patients; °3 patients not available; * ≥ 20 g/day during at least 6 consecutive months life-time; IQR, interquartile range; HCC,
hepatocellular carcinoma.
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HIV therapy had the highest proportion of GC regimens
(79.2%), cirrhotic patients the lowest (65.6%). These
figures tended to be statistically significant (p =0.08).
Patients with an indication for anti-HIV therapy and
on GC group were 202, 186 (92.1%) were using cART
with TDF plus LAM/FTC as backbone. Fifteen (7.4%)
others were on cART containing TDF, and 1 patient with
triple HCV co-infection was currently treated with PEG-
IFN. Comparable figures of cART with TDF plus LAM/
FTC were observed either among the 21 cirrhotic patients
currently on GC group (100%) or among the 30 patients
with no indication for anti-HIV therapy (n = 26, 86.7%).
Three (10%) of these latter patients were consistently
treated with LdT, and 1 with PEG-IFN. Patients retreated
for HBV co-infection and currently on GC group were
86. Sixty-eight (79.1%) had been previously treated with
LAM, and 18 with an interferon-based regimen.Patients falling into GU group were 78 (23.4%). LAM
(n = 60, 76.9%) within cART was the most common
anti-HBV regimen. Thirty-four (56.7%) of them showed
HBV DNA load below 1×103 IU/mL. Both interferon-
based regimens and combo NUC were taken by 4 (5.1%)
patients. ETV or LdT as mono-therapy were used by 3
patients (3.8%), respectively. Two (2.6%) patients were
either on TDF or ADV.
We also analyzed possible factors significantly associated
with unlisted anti-HBV regimens. A logistic regression
model (Table 5) revealed that a previous anti-HBV treat-
ment and a triple HDV co-infection reduced the chance of
GU regimens (aOR 0.4, 95% CI 0.19-0.83, p =0.01; aOR
0.41, 95% CI 0.18-0.93, p =0.03, respectively). Conversely,
age at HBV diagnosis and triple HCV co-infection were in-
dependently associated with an increased OR of being in-
consistently treated (aOR 1.23, 95% CI 1.02-1.48, p =0.03;
aOR 2.74, 95% CI 1.39-5.41, p =0.004, respectively).
Table 2 Logistic regression model in 427 patients with
HIV/HBVco-infection according to anti-HBV treatment
status
Never treated vs treated
patients adjusted OR
Characteristics (95% CI) P
N. enrolled per center§
≥20 patients 1.41 (0.73-2.71) 0.31
Female gender 0.83 (0.39-1.77) 0.64
Immigrant status
Foreign birth 0.74 (0.3-1.8) 0.51
Age at diagnosis
10 years increase 0.78 (0.55-1.11) 0.17
Years since diagnosis* <0.001
2-10 0.17 (0.08-0.36)
<10 0.08 (0.03-0.25)
Alcohol consumption
Ever 1.51 (0.63-3.62) 0.35
Disease stage°
cirrhosis/HCC 0.39 (0.09-1.78) 0.22
HBeAg
positivity 0.57 (0.28-1.14) 0.11
HCV co-infection
yes 0.91 (0.41-2.02) 0.82
HDV co-infection
yes 0.48 (0.14-1.66) 0.25
Reference: § = ≤20 patients enrolled; * = <2 years;° = chronic hepatitis. OR, odds
ratio; CI, confidence interval; HCC, hepatocellular carcinoma.
Table 4 Distribution of 334 HIV/HBV co-infected patients
on current anti-HBV treatment according to EACS
treatment guidelines
EACS GC
regimens
EACS GU
regimens
n % n %
No indication for anti-HIV therapy 30 68.2 14 31.8
Indication for anti-HIV therapy° 202 79.2 53 20.8
Indication for anti-HIV therapy not known§ 2 – – –
Cirrhotic/HCC 21 65.6 11 34.4
Total 255 76.6 78 23.4
EACS, European AIDS clinical society; GC, guideline consistent; GU, guideline
unlisted; °according to EACS guidelines for HCV co-infection [6], 1 patient with
triple HCV co-infection on PEG-IFN was considered as “consistent”; §3 patients:
2 on TDF plus LAM/FTC considered as “consistent”, 1 not classifiable.
Table 5 Logistic regression model of the odds ratio of the
EACS Guidelines Unlisted regimens in 333 HIV/HBV co-
infected patients currently on anti-HBV treatment
Characteristics EACS GU regimens adjusted OR
(95% CI) P
N. enrolled per center§
≥20 patients 0.56 (0.23-1.37) 0.2
Female gender 1.92 (0.71-5.18) 0.2
Immigrant status
Foreign birth 1.4 (0.71-2.74) 0.33
Age at diagnosis
10 years increase 1.23 (1.02-1.48) 0.03
Years since diagnosis* 0.12
2-10 0.68 (0.24-1.9)
<10 1.08 (0.39-3.04)
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and CD4 cels count of GC patients those of patients on
not consistent anti-HBV regimens. Only HBV DNA
levels were statistically different (p = 0.03). In particular,
proportion of HBV DNA load below median valueTable 3 Distribution of antiviral regimens among 334
HIV/HBV co-infected patients on current anti-HBV
treatment
Treatment n (%)
TDF + LAM/FTC 235 70.4
LAM 60 18
TDF 17 5.1
Telbivudine 6 1.8
PEG-IFN§ 6 1.8
Other combo NUC* 5 1.5
ETV 3 0.9
ADV 2 0.6
Total 334 100
§ + TDF = 4; *ADV + LAM =4, ADV + ETV =1.
Alcohol consumption
Ever 2.21 (0.84-5.86) 0.11
Disease stage°
Cirrhosis/HCC 1.57 (0.75-3.29) 0.23
HBeAg
Positivity 0.83 (0.44-1.55) 0.56
HCV co-infection
Yes 2.74 (1.39-5.41) 0.004
HDV co-infection
Yes 0.41 (0.18-0.93) 0.03
Previous treatment
Yes 0.4 (0.19-0.83) 0.01
Reference: § = ≤20 patients enrolled; * = <2 years;° = chronic hepatitis. EACS,
European AIDS Clinical Society; OR, odds ratio; CI, confidence interval; HCC,
hepatocellular carcinoma.
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treated and 52.2% among NGC patients.
Discussion
Features of HIV/HBV co-infected patients enrolled in
this cross-sectional study (Table 1) are consistent with
those observed in other Italian surveys of co-infected pa-
tients cared for by IDCs, such as the proportion of
HBeAg-negative cases, and of patients triple co-infected
with HCV or HDV [18-20].
Our study shows that in Italy approximately 90% of
the HIV/HBV co-infected patients managed by IDCs re-
ceive anti-HBV treatment at some point in their life.
This figure may be considered remarkably high when
taking into account that until a few years ago HIV co-
infection had been a factor hampering treatment of viral
chronic hepatitis even in industrialized countries with
free-drug supply [21,22]. The introduction of TDF plus
LAM/FTC, which has also a potent activity against HBV,
as an antiretroviral “backbone” largely contributed to in-
crease the proportion of co-infected patients treated for
HBV co-infection [23]. This is confirmed by our obser-
vation that this NUC combination was the most com-
mon regimen used (Table 2).
When demographic, clinical and virological character-
istics were entered in a logistic regression model we
found that the adjusted ORs of getting HBV antiviral
treatment were significantly increased by six times for
patients with HBV diagnosis known since 2–10 years
(p <0.001) and by more than twelve times for patients
with diagnosis known >10 years (p <0.001) (Table 3).
Owing to the natural history of chronic hepatitis B, these
differences may be considered expected.
The finding that in the field of HIV co-infection the
chance to receive anti-HBV therapy is not reduced in
potentially disadvantaged populations is intriguing. In
fact, inequalities not related to the severity of disease
limiting access to therapy are attenuated but not com-
pletely eliminated also in those countries with universal
coverage [24-26]. Since 1990, in Italy, only IDCs have the
duty to dispense comprehensive care for HIV-positive pa-
tients with all the costs covered centrally by a government
payer. This favored the practice of groups of infectious
diseases specialists able to cope with the vast majority of
treatment decisions regarding HIV infection and its re-
lated conditions. This unique Italian policy of caring for
HIV-infected patients played a crucial role either in en-
hancing the proportion of co-infected patients treated or
in reducing significant factors which may limit access to
anti-HBV therapy [8].
In our cohort approximately 40% of the treated pa-
tients for HBV infection had an history of past treat-
ment, and of these, 75% were on their second/other
regimen. Treatment history showed a clear reductionover time of patients using interferon. Reasons may be
the high incidence of adverse effects, along with the very
low sero-conversion rates of HBeAg or HBsAg observed
among HIV/HBV co-infected patients receiving curative
regimens as interferon [27,28]. Meanwhile, evidences
showed a correlation between prolonged period of cART
with dual activity and HBeAg or HBsAg sero-conversion
[29,30]. Accordingly, two-thirds of our patients who had
been previously on either lamivudine or interferon expe-
rienced a switch to TDF plus LAM/FTC. Overall, the
proportion of current TDF plus LAM/FTC regimens
was twelve times higher than that observed in past anti-
HBV treatments.
Our analysis shows that regimens received by 76.6% of
HIV/HBV co-infected patients compares favorably with
recommendations of EACS guidelines (Table 4). This is
despite the fact that co-infected patients present mul-
tiple challenges, recommendations regarding the choices
of anti-HBV therapy were evolving, and specific EACS
guidelines were being published during the enrollment
period of this study.
We found that more than two-thirds of patients with no
indication for anti-HIV therapy were consistently treated,
the overwhelming majority of them having started early
cART. As 2008 EACS guidelines were the first to clearly
recommend in HBV co-infected patients cART initiation
irrespective of CD4+ cells count, it is conceivable that
expert clinicians were able, under certain circumstances,
to choose regimens later included in guidelines. On the
other hand, due to their greater risk of death, proportion
of GC treatment should be increased in cirrhotic patients.
Interestingly, GC regimens were more likely to reach the
goal to significantly decrease HBV DNA load.
Nevertheless, a sizeable minority of patients was on a
suboptimal anti-HBV treatment, the majority (n =60,
77%) on LAM alone. The finding that more than half on
them showed low levels of HBV DNA load suggests that
in some patients clinicians seemed to change a regimen,
which involves also HIV suppression, only if these mea-
surements started to deteriorate.
Due to the predominance of intravenous drug users
among HIV/HCV co-infected patients in Italy [31], it is
conceivable that high rates of drug addiction among these
patients may contribute to increase the rate of suboptimal
treatments. Our findings that HCV co-infection increased
of more two times (p = 0.004) the chance of falling into
the GU group (Table 5), with triple co-infected patients
representing approximately half of those on not consistent
LAM stress the issue of adherence. Unfortunately, infor-
mation on route of infection was not asked for. Con-
versely, our observation that the chance of sub-optimal
treatment was significantly lower (p = 0.01) in patients on
second line anti-HBV regimen confirms the practice of
switching towards optimal regimens when available made
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known to be at an increased risk of an unfavorable out-
come, also had a decreased risk (p = 0.03) to be classified
into GU group.
This study has limitations, mainly deriving from the
design of the study. Our cohort was not randomly sam-
pled, and recruitment of the IDCs was voluntary-based.
Therefore, we cannot rule out the possibility that enrolled
patients was not representative of the entire population of
co-infected patients cared for by the participating centres.
Nevertheless, the proportion of patients who denied the
anonymous collection of medical data from their charts
was very small, and the study was conducted in those
IDCs where the majority of HIV-infected individuals are
cared for [32].
We were unable to investigate the reasons for and the
period of treatment change. No information was avail-
able regarding socio-economic, or educational distribu-
tion of the cohort. Nor did we had information on the
reasons for not receiving antiviral treatment, such as pa-
tient refusal.
Using Multiple Imputation, we were able to exploit all
the information available and avoid the drawbacks (loss
in precision and potential bias of the estimates) related
to the exclusion from the analysis of the patients who
had missing information on any of the predictors. Ex-
trapolations of our results to clinical settings of other
developed countries must be carried out with caution.
It is also possible that patients could have received
treatment at outside facilities. However, the high propor-
tion of treated patients by participating centres makes
likelihood for the receipt of treatment at other settings
very low.
Conclusions
Although further long-term studies need to be per-
formed to confirm our observations, results of our ana-
lysis have practical implications. A health system aimed
at providing free of charge and comprehensive care for
HIV-infected individuals by groups of specialists allows
to dispense anti-HBV therapy to a very high proportion
of co-infected patients in absence of disparities which
limit access to treatment. In order to slow progression of
HBV disease in co-infected patients, expert physicians
understand the need to quickly implement specific guide-
lines, and in some cases even to anticipate them. Neverthe-
less, our study identified scenarios in which clinical practice
deviates from updated recommendations, as in case of low
adherence or sub-optimal regimens with effective anti-HBV
response.
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